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Background: Huntington disease was one of the first neurological hereditary diseases for which genetic testing
was made possible as early as 1993. The study describes the clinical and genetic characteristics of patients with
Huntington disease in Sri Lanka.
Methods: Data of 35 consecutive patients tested from 2007 to 2012 at the Human Genetics Unit, Faculty of
Medicine, University of Colombo was analyzed retrospectively. Clinical data and genetic diagnostic results were
reviewed. Statistical analysis was performed using descriptive statistics.
Results: Thirty patients had fully penetrant (FP) CAG repeat mutations and 5 had reduced penetrant (RP) CAG
repeat mutations. In the FP group mean ages of onset and diagnosis were 37.5 and 40.4 years, while in the RP
group it was 63.0 and 64.8 years respectively. The age of diagnosis ranged from 15 to 72 years, with 2 patients with
Juvenile onset (<20 years) and 3 with late onset (>60 years) Huntington disease. The symptoms at diagnosis were
predominantly motor (32/35 -91%). Three patients had psychiatric and behavioral disorders. The age difference
between onset and genetic diagnosis showed significant delay in females compared to males (p < 0.05). Twenty
two (62.8%) had a positive family history, with 13/22 (59.1%) showing a paternal inheritance of the disease. In both
groups, those with a family history had a significantly lower age of presentation (p < 0.05). The mean CAG repeat
length in patients with FP alleles was 44.6 ± 5 and RP alleles was 37.2 ± 1.1. Age of onset and CAG repeat length of
the HTT gene showed significant inverse correlation (p < 0.0005, R2 = 0.727).
Conclusions: The clinical and genetic features seen in patients with Huntington disease in the Sri Lankan study
population were similar to that previously reported in literature.
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Huntington disease is a progressive neurodegenerative
disease. The causative mechanism is dominant inheritance
of a mutant (CAG)n triplet repeat expansions [1]. The dis-
ease manifests as motor disturbances such as impaired co-
ordination, gait ataxia, chorea, dystonia, bradykinesia and
rigidity, cognitive decline and neuropsychiatric symptoms
[2]. The age of onset is inversely related to the CAG repeat
length. This relationship accounts for 50 – 70% of the age
variance but does not provide information on the initial
symptoms, course or duration of the disease [3].
Worldwide prevalence of HD is 2.71 per 100,000 with
wide geographical variation. Population studies suggest* Correspondence: vajirahwd@hotmail.com
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distribution, and reproduction in any mediumthat the mutations originated in Europe. According to a
meta analysis performed by Pringsheim et al the highest
prevalence is seen in populations of Western European
descent with a prevalence of 5.7 per 100, 000. Asian
prevalence is low with studies indicating a prevalence of
0.4 per 100,000 [4].
This study is the first report on clinical and genetic
data characteristics of Huntington patients in Sri Lanka.Methods
Records of a total of 35 consecutive patients seen from
June 2007 to February 2012 were retrospectively assessed.
They were outpatients in our genetics clinic referred by
either neurologists or psychiatrists. The patients were
undergoing routine genetic diagnostic testing for their
disorder. They all gave written informed consent forntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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were offered post test counseling after test results were
known. Ethical approval for the study was obtained
from the Ethics Review Committee, Faculty of Medicine,
University of Colombo.
The patient sample included symptomatic patients with
motor symptoms, cognitive decline, and/or psychiatric
symptoms with or without a family history. Clinical data
on gender, age of onset of symptoms and signs, age at gen-
etic diagnosis and CAG repeat length were collected.
Genetic diagnosis was done by florescent based PCR
for detection of the CAG repeat length from the 5’ region
of the HTT gene. The size of the alleles was determined
using internal size markers with relative allele peak area
calculation [5]. Figure 1 shows the results of non affected
and affected patients in the study population. Alleles with
a CAG repeat length of 36 – 39 was defined as reduced
penetrant (RP) and ≥ 40 as fully penetrant (FP). Allele
length less than 36 was considered nonpathogenic [6].
Statistical analysis was conducted using descriptive
statistics, x2 analysis and Student’s t – test. Statistical
significance level was set at p < 0.05.
Results
HD patients with fully penetrant (FP) CAG repeat alleles
Clinical features
Of a total of 35 patients 30 had fully penetrant (FP)
CAG repeat alleles, of which 14 (46.7%) were male. Age
of onset of the disease was 37.5 ± 10.2 years (range 15–55).
The mean age at genetic diagnosis was 40.3 ± 10.6 yearsA
B
C
Figure 1 Electrophoretogram of a patient at risk for HD. Several shado
intensity measurement the main bands can easily be determined. The inte
numbers. In this figure A, B and C depict a non-affected individual, a reduc
repeat mutation carrier. Bands with 90, 159 and 168 bp were detected and(range 15–57) (Table 1). Time period between onset and
diagnosis was significantly delayed in FP females com-
pared to males (3.9 ± 3.6 and 1.6 ± 1.2 years) (p < 0.05).
Juvenile onset HD was seen in 2 patients, with paternal in-
heritance and onset in adolescence (ages 15 and 17 years).
Clinical symptoms at genetic diagnosis include dystonia
and parkinsonian features, typical of juvenile onset HD.
Positive family history was seen in 22/30 (70%) of patients
with paternal inheritance in 13/22 (62%). A significantly
lower age of diagnosis was seen in the presence of a posi-
tive family history (p < 0.05).
Genetic features
The mean CAG repeat length in the FP patient group was
44.6 ± 5. Heterozygous allele mutation was seen in all
positive patients. There was no significant difference in
the CAG repeat length in those with and without a posi-
tive family history. The two patients with Juvenile HD had
CAG repeat lengths of 59 and 61 respectively. The inverse
relationship of age at onset and CAG repeat length is
shown in Figure 2 with an adjusted R-square value of 0.727.
HD patients with reduced penetrant (RP) alleles
Reduced penetrant alleles were present in 5 patients, 4
women and one male. Age of onset and age at diagnosis
were significantly higher compared to the fully penetrant
allele population (p < 0.0005). Positive family history was
present in one patient only. Late onset HD (>60 years)
was seen in 3 (60%) patients with CAG repeat lengths
ranging from 36–38.w bands can be seen around the main allele bands, but based on the
rnal size control (not shown) allows the accurate sizing of CAG repeat
ed penetrant CAG repeat mutation carrier and a fully penetrant CAG
belong to 15, 38 and 41 CAG repeat numbers respectively.




Mean CAG repeats 44.6 ± 5 37.2 ± 1.1
Sex M = 21 (46.7%) M = 1 (20%)
Mean age at onset 37.5 ± 10.2 63.0 ± 6.8
Mean age at diagnosis 40.3 ± 10.6 64.0 ± 6.8
Positive FH 21/30 1/5
Age of diagnosis 40.4 ± 10.8 64 ± 6.8
Positive FH 38.1 ± 11.5 57
Negative FH 45.2 ± 6.6 65.8 ± 6.4
Duration from onset to diagnosis
Male 1.6 ± 1.1 0
Female 3.9 ± 3.6 1.25 ± 0.5
FP = Fully penetrant allele group.
RP = Reduced penetrant allele group.
N = Numbers, M =Males.
FH = Family History.
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Three patients presented for genetic testing of HD with
a history of behavioral symptoms (3/35 - 8.6%). One pa-
tient had reduced penetrant alleles with an age of onset
of 56 years while two had FP alleles and ages of onset of
35 and 36 years.Figure 2 Inverse relationship present between the age of onset of thDiscussion
Results in this first study of HD patients in Sri Lanka
showed that clinical and genetic data are similar to pre-
vious reports. There is, however, a recruitment bias, as
this is a retrospective study where only patients referred
to the single government based genetic centre situated
in Colombo were included. This means that patients
from remote regions of the country may not have been
referred for diagnosis. Further studies are needed for an
epidemiological overview of Huntington disease in Sri
Lanka.
HD with FP alleles
A complex gender based effect on the phenotypic expres-
sion of Huntington disease was evidenced by Zielonka
et al. A more sever phenotype and faster rate of progres-
sion was seen in women especially in the motor and func-
tional domains [7]. In our study, however, females had a
significantly later presentation to clinic for diagnosis com-
pared to males. This could be either because there was
not a rapid progression of disease in these women con-
trary to previous reports, or because of social factors inter-
vening and delaying presentation in females. Determining
the precise cause must be investigated further.
Nine of the thirty patients (30%) did not have a positive
family history of HD. This is similar to previous reports,
among them Creighton’s and colleagues comprehensivee disease and CAG repeat numbers.
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affected individuals had a negative family history [8,9].
Possible reasons for negative family history are new muta-
tion, non – paternity including adoption not known to the
affected subject, a parent dying prior to the onset of symp-
toms or failure to diagnose disease in a parent. Our study
design did not, however, allow for further investigation of
the specific reasons.
Genetic features
An inverse relationship was present between the age of
onset of the disease and CAG repeat numbers. (Adjusted
R2 squared = 0.727, p < 0.0005), as expected from previous
reports, such as 0.85 in a large cohort of Venezuelan kin-
dred [10], and 0.642 in North American, Australian and
European populations [4]. Studies analyzing the onset of
symptoms in HD have shown a 70% contribution from
CAG repeat length. The remaining variations have been
shown to be due to modifier genes and environmental fac-
tors, which may account for the disparities seen in differ-
ent populations [10-12]. We did not investigate further
genetic and environmental factors which may differentiate
the affected from the non – affected subjects in our study
population.
HD with RP alleles
Patients in the RP group of our study population had a
lower prevalence of positive family history than the FP
group. Ages of onset were also significantly higher. Studies
indicate that more than 20% of individuals with reduced
penetrant alleles remain undiagnosed due to their mild
clinical phenotype [13]. As reported in previous studies,
we found a smaller percent with RP in our population
(14%) [14]. This indicates that many patients with RP
alleles may not be receiving genetic testing in the
population.
Patients presenting with behavioral symptoms
Surprisingly, there were only 8% of patients in our study
with predominantly behavioral symptoms. This is much
lower than previously reported prevalence, estimated at
approximately 23 - 36% [15]. It is thought to have a two-
fold etiology, biological and psychosocial [16]. Symptoms
which include depression, delusions, hallucinations, sex-
ual dysfunction and suicidal ideation are thought to be
the earliest presentations of the disease [17]. This low
prevalence in our study may indicate the existence of a
hidden patient population with behavioral symptoms
that are not receiving diagnostic services for Huntington
disease. In other words, there may well be a bias caused
by lack of identification and diagnosis of the problem.
Though studies indicate that behavioral symptoms are
the earliest markers of Huntington disease, in our studyages of presentation were not significantly lower than
those presenting with motor symptoms [17]. This may
be due to the reduced number of patients seen in the
study.Conclusion
This study shows that correlation of CAG repeat num-
ber with age of onset is similar to that seen in popula-
tions reported in literature. However, discrepancies with
previous reports in age of women presenting for diagnosis
and prevalence of behavioral symptoms warrant further
studies in the Sri Lanka HD population.
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